1. Case report: BRAF A598-T599insV mutation as a potential resistance mechanism to alectinib in ALK-rearranged lung adenocarcinoma
- Author
-
Thomas Pasau, Els Wauters, Isabelle Wauters, Fabrice Duplaquet, Lionel Pirard, Claudia Pop-Stanciu, Nicky D’Haene, Michael Dupont, Thierry Vander Borght, Benoît Rondelet, and Sebahat Ocak
- Subjects
ALK rearrangement ,BRAF A598-T599insV mutation ,lung adenocarcinoma ,resistance to alectinib ,non-small cell lung cancer ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) have improved the prognosis of advanced-stage non-small cell lung cancer (NSCLC) with ALK rearrangement, but resistance mechanisms limit their efficacy. We describe the case of a 63-year-old man with a stage cIVA ALK-rearranged lung adenocarcinoma who developed a BRAF A598-T599insV mutation as a potential resistance mechanism to alectinib, a second-generation ALK TKI. He was treated with an association of BRAF and MEK inhibitors but death occurred two months after treatment initiation in a context of tumor progression and toxicity. Based on this first report of BRAF A598-T599insV mutation occurring in lung cancer, we discuss resistance mechanisms to ALK TKIs, implications of BRAF mutation in NSCLC, and BRAF A598-T599insV mutation in other cancers.
- Published
- 2022
- Full Text
- View/download PDF